An official website of the United States government
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Ustekinumab (Stelara) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Apr.
| Drug | Ustekinumab (Stelara) |
|---|---|
| Indication | For the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, loss of response to, or were intolerant to either immunomodulators or one or more tumour necrosis factor-alpha antagonists, or have had an inadequate response, intolerance or demonstrated dependence on corticosteroids. |
| Reimbursement request | As per indication. |
| Dosage form(s) | 130 mg solution for intravenous infusion (for induction period) 90 mg solution for subcutaneous injection (for maintenance period) |
| NOC Date | December 12, 2016 |
| Manufacturer | Janssen Inc. |
Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/
Your browsing activity is empty.
Activity recording is turned off.
See more...
